These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 19393384

  • 1. [Severe forms of depression: the efficacy of escitalopram].
    Spadone C.
    Encephale; 2009 Apr; 35(2):152-9. PubMed ID: 19393384
    [Abstract] [Full Text] [Related]

  • 2. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC.
    Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
    [Abstract] [Full Text] [Related]

  • 3. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients.
    Boulenger JP, Huusom AK, Florea I, Baekdal T, Sarchiapone M.
    Curr Med Res Opin; 2006 Jul; 22(7):1331-41. PubMed ID: 16834832
    [Abstract] [Full Text] [Related]

  • 4. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P.
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [Abstract] [Full Text] [Related]

  • 5. Superiority of escitalopram to paroxetine in the treatment of depression.
    Kasper S, Baldwin DS, Larsson Lönn S, Boulenger JP.
    Eur Neuropsychopharmacol; 2009 Apr; 19(4):229-37. PubMed ID: 19185467
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY, Belous AI, Yevtushenko YG, Gusinin SE, Buzik OJ, Agibalova TV.
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [Abstract] [Full Text] [Related]

  • 7. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder.
    Bose A, Korotzer A, Gommoll C, Li D.
    Depress Anxiety; 2008 Nov; 25(10):854-61. PubMed ID: 18050245
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy of escitalopram and severity of depression: new data].
    Spadone C.
    Encephale; 2009 Dec; 35(6):577-85. PubMed ID: 20004289
    [Abstract] [Full Text] [Related]

  • 9. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P, Andersen HF, Wade A.
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of escitalopram in patients with severe depression: a pooled analysis.
    Llorca PM, Azorin JM, Despiegel N, Verpillat P.
    Int J Clin Pract; 2005 Mar; 59(3):268-75. PubMed ID: 15857321
    [Abstract] [Full Text] [Related]

  • 11. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
    Pigott TA, Prakash A, Arnold LM, Aaronson ST, Mallinckrodt CH, Wohlreich MM.
    Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
    [Abstract] [Full Text] [Related]

  • 12. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder.
    Colonna L, Andersen HF, Reines EH.
    Curr Med Res Opin; 2005 Oct; 21(10):1659-68. PubMed ID: 16238906
    [Abstract] [Full Text] [Related]

  • 13. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P, Legault M.
    Depress Anxiety; 2008 Oct; 25(12):E173-81. PubMed ID: 19006260
    [Abstract] [Full Text] [Related]

  • 14. A cost-effectiveness model of escitalopram, citalopram,and venlafaxine as first-line treatment for major depressive disorder in Belgium.
    Demyttenaere K, Hemels ME, Hudry J, Annemans L.
    Clin Ther; 2005 Jan; 27(1):111-24. PubMed ID: 15763612
    [Abstract] [Full Text] [Related]

  • 15. Escitalopram for the treatment of major depression and anxiety disorders.
    Höschl C, Svestka J.
    Expert Rev Neurother; 2008 Apr; 8(4):537-52. PubMed ID: 18416657
    [Abstract] [Full Text] [Related]

  • 16. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD).
    Wade AG, Schlaepfer TE, Andersen HF, Kilts CD.
    J Psychiatr Res; 2009 Feb; 43(5):568-75. PubMed ID: 18954875
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
    Schmitt L, Tonnoir B, Arbus C.
    Neuropsychobiology; 2006 Feb; 54(4):201-7. PubMed ID: 17337913
    [Abstract] [Full Text] [Related]

  • 18. The effect of escitalopram on sleep problems in depressed patients.
    Lader M, Andersen HF, Baekdal T.
    Hum Psychopharmacol; 2005 Jul; 20(5):349-54. PubMed ID: 15912558
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of escitalopram vs. citalopram in major depressive disorder.
    Fantino B, Moore N, Verdoux H, Auray JP.
    Int Clin Psychopharmacol; 2007 Mar; 22(2):107-15. PubMed ID: 17293711
    [Abstract] [Full Text] [Related]

  • 20. Escitalopram in the treatment of anxiety symptoms associated with depression.
    Bandelow B, Andersen HF, Dolberg OT.
    Depress Anxiety; 2007 Mar; 24(1):53-61. PubMed ID: 16937393
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.